Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VIP and tolerance induction in autoimmunity.

F Rosignoli1, M Torroba, Y Juarranz

  • 1Dept. Biología Celular, Facultad de Biologia, UCM 28040 Madrid, Spain.

Annals of the New York Academy of Sciences
|August 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Is severity related to the utilization of resources? An exploration of the Duke Severity of Illness Scale (DUSOI)].

Atencion primaria·1998
Same author

Transfusion-related acute lung injury associated with an NA1-specific antigranulocyte antibody.

Haematologica·1998
Same author

The two poles of the lymphocyte: specialized cell compartments for migration and recruitment.

Cell adhesion and communication·1998
Same author

Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.

British journal of cancer·1998
Same author

Delayed-type hypersensitivity to subcutaneous enoxaparin.

Allergy·1998
Same author

Occupational asthma by Anisakis simplex.

The Journal of allergy and clinical immunology·1998
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

Vasoactive intestinal peptide (VIP) prevents type 1 diabetes in nonobese diabetic mice by reducing inflammation and promoting regulatory T cells. VIP treatment restores immune tolerance to pancreatic islets, offering a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetes Research

Background:

  • Vasoactive intestinal peptide (VIP) exhibits potent anti-inflammatory and immunoregulatory properties.
  • VIP influences immune responses by promoting a Th2 cytokine profile.

Purpose of the Study:

  • To investigate the therapeutic potential of VIP in preventing type 1 diabetes.
  • To elucidate the immunomodulatory mechanisms underlying VIP's protective effects in a mouse model.

Main Methods:

  • Treatment of nonobese diabetic (NOD) mice with VIP starting at 4 weeks of age.
  • Assessment of diabetes incidence, insulitis severity, and cytokine profiles.
  • Analysis of regulatory T cell markers (FoxP3, TGF-beta) and Th1 transcription factor (T-bet) in pancreatic tissues.

Related Experiment Videos

Main Results:

  • VIP treatment completely prevented diabetes development in NOD mice.
  • VIP-treated mice exhibited significantly milder insulitis compared to controls.
  • VIP administration reduced circulating Th1 cytokine levels.
  • Pancreatic tissues showed increased expression of regulatory T cell markers (FoxP3, TGF-beta) and decreased T-bet.

Conclusions:

  • VIP effectively prevents type 1 diabetes in a preclinical model.
  • VIP restores immune tolerance to pancreatic islets by promoting local regulatory T cell differentiation and function.
  • VIP represents a promising therapeutic candidate for type 1 diabetes treatment.